VANGUARD PRIMECAP CORE FUND

VANGUARD FENWAY FUNDS · Series S000002581 · 1 share classes

Equity fund · 98% stocks
One fund, 1 share classes:VPCCX
$13.54B NAV
181 positions · as of 2026-03-31 · filed 2026-05-28
data updated 2026-08-17

Fund profile

As filed in the prospectus · 2026 Q1

Vanguard PRIMECAP Core Fund (the Fund) seeks to provide long-term capital appreciation.

Strategy · summarised

The fund employs active management to select stocks offering reasonable valuations paired with growth prospects the advisor believes the market has underpriced relative to peers. It invests across all sectors and market capitalizations, with up to 25% of assets permitted in foreign securities. Because returns depend on the manager's security selections and valuations may not materialize as expected, performance will diverge from broad market benchmarks.

Expenses
0.37%one share class
Share classExpense ratio
VPCCX0.37%

Portfolio turnover 11.00% · as of 2026 Q1

Allocation

Asset groups · long / short shown separately, never netted · 2026 Q1

100.07%
of net assets
Stocks97.75%
Cash & short-term2.33%

Latest quarter

What changed since the fund's previous filing

2026Q1 vs 2025Q4: 10 new5 exited

Largest new: AstraZeneca PLC, Roche Holding AG, BA, WM, FITB, LHX, MRSH, XEL

Exited: AstraZeneca PLC, Roche Holding AG, CMA, SOLS, LESL

Return profile

Total return as filed — price change plus distributions reinvested · trailing figures to Feb 2026

1-year
3-year
5-year
Volatility
Worst 3-yr fall
Cumulative return· Apr 2023 – Feb 2026

Mar 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

Holdings

By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page

Issuer%NAVValue
Eli Lilly & CoLLY5.42%$734.07M
Micron Technology IncMU4.03%$545.20M
AstraZeneca PLC3.47%$469.59M
Alphabet IncGOOGL2.97%$402.18M
Flex LtdFLEX2.97%$401.90M
Intel CorpINTC2.83%$383.76M
KLA CorpKLAC2.44%$329.94M
Vanguard Cmt Funds-Vanguard Market Liquidity Fund2.33%$315.02M
Microsoft CorpMSFT2.18%$295.09M
Amgen IncAMGN1.92%$259.45M
Showing 10 of 181Sign in to see more

Reported price is the fund's own reported value divided by its own reported shares at 2026-03-31 — not a live quote, and not what the fund paid.

Top 10 positions are 30.54% of net assets, top 25 53.09%, across 180 issuers.

See more of this fund's book

More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.

Sign in free